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Abstract
Background: At least one-third of epithelial ovarian cancers are associated with the development of ascites containing
heterogeneous cell populations, including tumor cells, inflammatory cells, and stromal elements. The components of
ascites and their effects on the tumor cell microenvironment remain poorly understood. This study aimed to isolate and
characterize stromal progenitor cells from the ascites of patients with epithelial ovarian adenocarcinoma (EOA).
Methods: Seventeen ascitic fluid samples and 7 fresh tissue samples were collected from 16 patients with EOA.
The ascites samples were then cultured in vitro in varying conditions. Flow cytometry and immunocytochemistry
were used to isolate and characterize 2 cell populations with different morphologies (epithelial type and
mesenchymal type) deriving from the ascites samples. The in vitro cell culture model was established using
conditional culture medium.
Results: The doubling times of the epithelial type and mesenchymal type cells were 36 h and 48 h, respectively,
indicating faster growth of the epithelial type cells compared to the mesenchymal type cells. Cultured in vitro,
these ascitic cells displayed the potential for self-renewal and long-term proliferation, and expressed the typical
cancer stem/progenitor cell markers CD44
high, CD24
low, and AC133
+. These cells also demonstrated high BMP-2,
BMP4, TGF-b, Rex-1, and AC133 early gene expression, and expressed EGFR, integrin a2b1, CD146, and Flt-4, which
are highly associated with tumorigenesis and metastasis. The epithelial type cells demonstrated higher cytokeratin
18 and E-cadherin expression than the mesenchymal type cells. The mesenchymal type cells, in contrast,
demonstrated higher AC133, CD73, CD105, CD117, EGFR, integrin a2b1, and CD146 surface marker expression than
the epithelial type cells.
Conclusion: The established culture system provides an in vitro model for the selection of drugs that target
cancer-associated stromal progenitor cells, and for the development of ovarian cancer treatments.
Keywords: human cancer initiating/stem cell, stromal progenitor cells, epithelial ovarian adenocarcinoma, epithe-
lial-mesenchymal transition
Background
Ovarian cancer is the fifth leading cause of death from
cancer in the Western world, and the leading cause of
death from gynecologic cancer. More than 90% of ovarian
cancers arise from the surface epithelium [1,2]. In Taiwan
ovarian cancer is the tenth leading cause of female malig-
nancy and the leading cause of death from gynecological
cancer. Seventy-five percent of epithelial ovarian cancer
(EOC) patients receive a diagnosis at the advanced stage,
and among these, at least one-third are associated with the
development of ascites, an abnormal collection of exudate
with a cellular fraction consisting mainly of cancer cells,
lymphocytes, and mesothelial cells [3,4]. Efforts at improv-
ing the survival of patients with EOC have focused on
early detection and on the development of novel che-
motherapeutic drugs. However, long-term survival of
patients with advanced ovarian cancer remains limited
(below 20%). Understanding the mechanisms underlying
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fore essential for the development of effective treatments.
Components of ascites, including neoplastic cells and
pro-angiogenic or tumorgenic factors, may contribute to
the proliferation and spread of cancer cells [5]. Results
from previous investigations indicate that in addition to
the neoplastic cancer cells, stromal cells that are hetero-
geneous and composed of fibroblasts, endothelial or
methothelial cells, adipocytes or adipose tissue-derived
stromal cells, bone marrow-derived stem cells, and
immune cells promote tumor growth, invasion, and
metastasis by cross-talk with cancerous cells [6,7]. Prior
research has established that ascites commonly develops
in patients with EOC, and that the presence of abnormal
stromal cells in the ascites may establish an unusual
microenvironment for tumor spreading. However, the
roles of these abnormal stromal cells in the development
of ovarian cancer remain poorly understood.
Tumor development is mainly associated with the accu-
mulation of multiple genetic and epigenetic alterations,
resulting in the transformation of a normal cell to a cancer
cell [8]. The components of tumors are complex, compris-
ing genetically or epigenetically altered tumor cells sur-
rounded by a heterogeneous population of stromal cells.
The cellular and molecular interactions between tumor
and stromal cells trigger tumor growth and metastatic
spreading [9]. Increasing evidence has suggested that the
growth capability of a tumor is dependent on cancer stem
cells or cancer initiating cells (CSCs/CICs), which repre-
sent a minority of cells within tumors [10]. Although
investigators proposed the existence of CSCs/CICs several
decades ago, it was not until 1997 that Bonnet et al. first
isolated these cells from patients with acute myeloid leuke-
mia [11]. Further studies subsequently described the isola-
tion of CICs from patients with prostate, melanoma, lung,
colon, and pancreas cancer [12-16]. CICs may be derived
from abnormal stem cells or from differentiated tumor
cells acquiring stem-like characteristics.
The epithelial origin of most ovarian cancers and co-
expression of epithelial and mesenchymal markers (keratin
and vimentin or N-cadherin, respectively) in EOC high-
light the importance of phenotypic and genetic plasticity of
the ovarian surface epithelium (OSE) during neoplastic
transformation and acquisition of stem cell characteristics
[17]. Recent studies have shown that epithelial mesenchy-
mal transition (EMT), which mediates changes in cell mor-
phology and involves the loss of cell adhesion and
acquisition of migratory and invasive properties through
an undefined mechanism, triggers the generation of CICs
from immortalized human mammary epithelia [18-20].
Disruptions to the normal barrier, which protects normal
OSE from underlying stromal signaling, may also promote
EMT, resulting in neoplastic transformation of the OSE
[21]. Hanahan and Weinberg detected several molecular
changes during EMT, including the loss of epithelial mar-
kers (E-cadherin) and the induction of mesenchymal mar-
kers (N-cadherin, fibronectin, and Snail) [8], and
implicated these changes in tumor recurrence. Stromal
progenitor cells from the ascites of patients with ovarian
cancer have been shown to promote the cancer tumori-
genecity and angiogenesis [22]. We thus aimed to isolate
and characterize stromal progenitor cells from the ascites
of patients with epithelial ovarian adenocarcinoma (EOA),
applying various in vitro culture conditions to obtain 2 dis-
tinct cell populations with different morphologies, the
epithelial and mesenchymal types, and comparing them
with the cells isolated from fresh cancer tissues of EOA
patients. The isolated cells with epithelial morphology and
epithelial-specific marker expression were more frequently
from the ascites of patients with early stage EOA, whereas
mesenchymal type cells were derived from the ascites of
the same patient with late stage EOA and recurrent
tumors. During the in vitro culture process, these cells dis-
played the potential for self-renewal and presented with
EMT capability.
Methods
Ascites collection from patients with epithelial ovarian
adenocarcinoma
The study protocol was approved by the Institutional
Review Board of Cathay General Hospital. Seventeen
patients with primary or recurrent epithelial ovarian can-
cer were recruited. Seventeen ascitic fluid samples and 7
fresh tissue samples were obtained from 16 EOA patients,
with ages ranging from 28 to 85 years, attending Cathay
General Hospital between May 2009 and January 2010.
Two normal ovarian tissue samples were obtained from
histologically proven normal ovaries of 2 patients with
early ovarian cancer. Histopathology, grade, and stage of
ovarian tumor were assigned according to the Federation
of Gynecology and Obstetrics criteria. Of the 17 ascitic
fluid samples included, 12 were from patients diagnosed
with ovarian serous adenocarcinoma (OSA), 3 were from
patients with ovarian clear cell adenocarcinoma (OCCA),
and 2 were from patients with ovarian mucinous border-
line tumor (OMBT). Table 1 shows details of the clinical
characteristics of the 16 patients from which the 17 ascitic
fluid samples and 7 fresh tissues samples were obtained.
An average of 20 mL ascites was harvested at laparotomy
or ultrasound-guided paracentesis was centrifuged to frac-
tionate the cellular component.
Isolation and in vitro culture conditions of ascitic cells
Cells from ascites samples of patients diagnosed with
malignant EOA were isolated using standard procedures.
Briefly, the ascitic fluid was centrifuged at room tem-
perature for 5 min at 1500 rpm. The cell pellet was
resuspended in 10-mL ovarian culture medium [basal
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10% FBS, EGF (10 ng/mL) and FGF-b1 (10 ng/mL) or
basal medium B: M199 medium supplemented with 10%
FBS, EGF (20 ng/mL) and hydrocortisone (0.4 μg/mL)]
for every 3 × 10
6 cells in a T75 flask. Cultures were
maintained in a humidified chamber with 5% CO2 at 37°
C, and the media were refreshed every 3 days to main-
tain the adherent cells. When the adhered cells reached
85% confluence, the cells were harvested with 0.25%
trypsin - 1 mM EDTA (Sigma-Aldrich, St. Louis, MO,
USA) treatment for 5 min.
Flow cytometric analysis
Expanded cells from ascites of patients with EOA were
characterized in vitro using flow cytometry (FACSCali-
bur, BD Biosciences, USA). Fluorescein isothiocyanate
(FITC)- or phycoerythrin (PE)-conjugated antibodies
against CD24 (BioLegend, CA, USA), CD44 (BioLegend),
AC133 (Miltenyi Biotec, CA, USA), CD73 (BD, CA,
USA), CD105 (Pharmingen), CD117 (eBioscience, CA,
USA), cytokeratin 18 (Dako), CXCR4 (Pharmingen),
EGFR (BioLegend), PDGFR (Pharmingen), intergrin
a2b1 (Abcam, CA, USA), CD146 (Abcam), FLT-4 (Bio-
Legend), and E-cadherin (BioLegend) were used.
Immunofluorescence analysis of markers for
mesenchymal and epithelial cells
Immunofluorescence analysis was performed on cells in
vitro at the third passage. Antibody against vimentin
(the mesenchymal marker (Dako); 1:250 dilution) or
against cytokeratin 18 (the epithelial marker (Dako);
1:250 dilution) were used, followed by FITC-conjugated
Table 1 Clinical characteristics of patients from which ascites were obtained and characteristic features of cells
isolated
Ascites Sample No. Age Histopathology Origin Stage Prior CT Clinical intervention Cell Morphology Percentage of cells with
CK-18 (+)/Vimentin (+)
1 85 OSA ascites IIIC yes Neoadjuvant CT Mesenchymal-like 6.5%/95.3%
2 54 OSA ascites IIIC yes Recurrence Epithelial-like 73.1%/11.2%
3 45 OSA ascites IIIC yes Recurrence Epithelial-like 79.8%/8.5%
4 62 OSA ascites IIIC No Primary surgery Mesenchymal-like 25.1%/85.5%
Epithelial-like 79.5%/9.2%
5 62 OSA ascites IC No Primary surgery Mesenchymal-like 21.3%/90.4%
6 57 OSA ascites, tissue IIC No Primary surgery Mesenchymal-like 15.3%/92.7%
4.8%/92.3%
7 46 OSA ascites IIIC Yes Recurrence Mesenchymal-like 21.4%/87.2%
8 48 OSA ascites IIIC No Primary surgery Mesenchymal-like 15.9%/91.5%
tissue 4.7%/97.5%
9 53 OSA ascites IIIC No Primary surgery Mesenchymal-like 24.3%/91.7%
tissue 3.5%/98.1%
10 48 OSA ascites IIIC No Primary surgery Mesenchymal-like 13.9%/94.5%
tissue 5.5%/94.8%
11 28 OMBT ascites IA No Primary surgery Mesenchymal-like 4.7%/98.9%
12(3) 45 OSA ascites IIIC yes Recurrence Mesenchymal-like 5.4%/93.5%
13(7) 46 OSA ascites IIIC Yes Recurrence Mesenchymal-like 1.3%/99.4%
14(11) 28 OMBT ascites IA Yes Recurrence Mesenchymal-like 4.2%/98.7%
15 37 OCCA ascites IC Yes Recurrence Mesenchymal-like 1.4%/97.1%
16 52 OCCA ascites IC Yes Secondary debulking Mesenchymal-like 6.2%/91.8%
17 71 OCCA ascites, tissue IIIC No Primary surgery Mesenchymal-like 8.2%/93.1%
3.2%/95.7%
18 61 OSA tissue IIIC no primary surgery Mesenchymal-like 4.3%/96.1%
19 73 OSA tissue IIIC no primary surgery Mesenchymal-like 7.1%/92.5%
20 N/A Endometriosis ascites N/A N/A N/A Mesenchymal-like 3.2%/97.8%
Epithelial-like 99.1%/3.4%
( ): Sample obtained from the same patient No.
OSA: ovarian serous adenocarcinoma; OCCA: ovarian clear cell adenocarcinoma; OMBT: ovarian mucinous borderline tumor
CT: chemotherapy
N/A: not applicable
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cence microscope. DAPI staining was used to localize
the nuclei.
Cell growth kinetics of isolated ascites cells
Isolated ascites cells were initially seeded in vitro at a
density of 10
5 cells in a T75 flask with 10 mL of com-
plete medium. Cells were harvested in log-phase
growth, at approximately 85% confluence using Tryp-
sin-EDTA (Sigma, T4174). The cell number was
counted using a hemocytometer. The growth fraction
(GF) was defined as the average growth rate in between
each 2 passages. The cell doubling time was calculated
by least squares regression analysis of a semi-logarith-
mic plot.
Isolation of normal ovarian and ovarian carcinoma tissue
cells
Normal ovarian and ovarian carcinoma tissues were
minced in Hank’s balanced salt solution (Invitrogen;
Grand Island, NY) and mixed with 1 mg/ml of collage-
nase 1A (Sigma, C9891) at 37°C for 60 minutes. The dis-
persed cells were filtered through a 70 ?m nylon mesh
(BD Bioscience) to remove the undigested tissue pieces,
and further centrifuged at 170 xg to obtain the cell pellet.
Isolated cells were initially seeded in vitro at a density of
5×1 0
4 cells per cm
2 in a T75 flask. Cells were sub-cul-
tured in log-phase growth, at approximately 80% conflu-
ence using Trypsin-EDTA (Sigma, T4174).
Results
Cells deriving from ascites of patients with EOA
expressed mesenchymal or epithelial cell-specific surface
markers
The present study isolated two different morphological cell
populations from EOA patients’ ascites, culturing in selec-
tive media. One population of cells was cobblestone shaped,
demonstrating epithelial-like morphology. The other was
spindle shaped, demonstrating mesenchymal-like cell
morphology (Figures 1 and 2, photos of phase-contrast
microscopic observations). Analysis of immuno-fluores-
cence staining revealed that the cells with mesenchymal
type morphology expressed vimentin, the mesenchymal
cell-specific marker, but not cytokeratin 18, which is speci-
fic to epithelial cells (Figure 1). In contrast, cells with
epithelial morphology expressed cytokeratin 18, but not
vimentin, in the cytosol (Figure 2). Cells sprouting from the
fresh ovarian cancer tissue or normal ovarian tissue sam-
ples showed mesenchymal-like morphology (Figures 3 and
4). In vitro culturing of EOA patient tissue produced a
spheroid-like formation of spindle-shaped cells, suggesting
the presence of tumor stromal progenitors (Figure 3). Simi-
lar observations occurred in cells cultured from the ascites
of the same patient (data not shown), indicating that the
mesenchymal type cells identified may originate from the
tumor stroma.
Flow cytometric analysis using antibodies against cell
surface molecules further characterized the ascites- or
tumor tissue-derived cells. Results showed that the cells
with mesenchymal-like morphology deriving from the
ovarian cancer tissues of patients with OSA had higher
CD31, CD117, CD106, AC133, and CD146 expression
and moderately increased CD34 and Flt-4 expression, but
lower CD24, CD49d, CD49f, EGFR, and SH2 expression,
compared to cells deriving from normal ovarian tissue
(Figure 5). Cells with mesenchymal-like morphology
deriving from normal and cancer tissues showed similar
levels of CD14, CD29, CD36, CD44, CD45, CD49e,
CD73, CDw90, CK18, FLT-1, STRO-1, SH4, HLA-ABC,
and integrin a2b1 expression (Figure 5). Cells with
mesenchymal- or epithelial-like morphology deriving
from the ascites of patients with OSA expressed similar
levels of CD44, AC133, CD146 and Flt-4 (Figure 6).
CD24, CD73, CD117 and integrin a2b1 expressions were
higher in the mesenchymal-like cells deriving from
ascites or cancer tissues than the normal HOTC, but
lower in epithelial-like cells from ascites. The epithelial-
like cells, in contrast, demonstrated higher cytokeratin 18
and E-cadherin expression (Figure 6). Expressions of
CD24 and PDGFR were reduced in both epithelial- and
mesenchymal-like cells deriving from ovarian ascites
(HOCAC) than those from normal ascites (HBAC).
Epithelial- and mesenchymal-like cancer cells deriving
from ascites both demonstrated the typical cancer stem/
progenitor cell characteristics of CD44
high,C D 2 4
low,a n d
AC133
+ as reported in ovarian cancer-initiating cells by
Zhang et al., and ovarian cancer stem cells by Alvero et
al. [23,24]. The mesenchymal-type identity was further
confirmed by specific surface molecule expressions in the
single-cell-derived clones (Figure 7).
Growth curves of ascites- or tumor tissue-derived cell
populations
Analysis of the growth characteristics of 2 cell popula-
tions with distinct morphology deriving from ascites of
different ovarian adenocarcinoma samples over a 5-week
in vitro culturing period revealed that the epithelial type
cells grew faster than the mesenchymal type cells. The
doubling time of the epithelial type cells was 36 h, com-
pared to a doubling time of 44 h in the mesenchymal
type cells deriving from ascites, and a doubling time of
56 h in cells from fresh cancer tissues (Figure 8). Both
cell populations could be cultured long-term in vitro for
more than 2 months (Figure 8).
Discussion
Current study describes two different types of tumors
cells with distinct mesenchymal-like and epithelial-like
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Page 4 of 10Figure 1 Immunostaining of ascites cells of a patient with ovarian adenocarcinoma (#13). Images (400×) of the ascites cells (passage 3,
cultured in medium B) from a patient with ovarian adenocarcinoma (#13), immunostained with antibodies against vimentin (mesenchymal cell
marker, green) or cytokeratin 18 (epithelial cell marker, green). DAPI (blue) was used to localize nuclei. A representative phase-contrast image
(100×) is also shown.
Figure 2 Immunostaining of ascites cells of a patient with ovarian adenocarcinoma (#2). Images (400×) of the ascites cells (passage 3,
cultured in medium B) from a patient with ovarian adenocarcinoma (#2), immunostained with antibodies against vimentin (mesenchymal cell
marker, green) or cytokeratin 18 (epithelial cell marker, green). DAPI (blue) was used to localize nuclei. A representative phase-contrast image
(100×) is also shown.
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derived from the ascites and tumor tissues of patients
with epithelial ovarian cancer. Both cell populations
were selected and cultured from the same adherent
cells. The mesenchymal type cells expressed vimentin (a
mesenchymal cell marker), whereas the epithelial type
cells expressed cytokeratin 18 (an epithelial cell marker),
as revealed by immunocytochemical and flow cytometric
analyses (Figures 1, 2, and 6). The mesenchymal-like
cells demonstrated higher CD73, CD117, and integrin
a2b1 surface marker expression than the epithelial-like
cells (Figure 6). These cells surrounded the aggregated
or spheroid tumor mass (Figure 3), suggesting that this
mesenchymal-like cell population may originate from
tumor stroma.
Downregulation of E-cadherin is a hallmark of the
epithelial mesenchymal transition (EMT). EMT progres-
sion in cancer cells is associated with the loss of certain
epithelial markers and the acquisition of a mesenchymal
phenotype, as well as migratory activities [18-20]. The
characteristics of both types of cells isolated in this
study resembled those of stem/progenitor cells for their
potential for self-renewal and expression of typical can-
cer stem/progenitor cell markers [25-28], including
CD44
high,C D 2 4
low,a n dA C 1 3 3
+ (Figures 7 and 8).
These two cell populations could be cultured long-term
Figure 3 Morphology of spheroid tumor stromal progenitor cells from fresh ovarian cancer tissues. Phase contrast images of ovarian
cancer cells (passage 2, cultured in medium B) deriving from patients with serous type adenocarcinoma: #6 (a: 40X; b: 100X), #8 (c: 40X), and #9
(d: 40X). All cells display the mesenchymal-like morphology of the ascites cells from the same patient, forming spheroid-like structures in most
observed fields.
Figure 4 Morphology of cells deriving from normal human ovarian tissue. Phase contrast images of cells (passage 2, cultured in medium
B) deriving from normal ovarian tissue of patients #1 (a: 40X) and #2 (b: 40X). Both display the mesenchymal-like morphology of the cancer cells
deriving from cancer tissue of patient #6 (c: 40X).
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cloned without losing their original identities (Figure 7).
Future investigative aims include the evaluation of the
tumorigenecity and metastatic ability of these two cell
populations in nude mice to further understand their
characteristics.
Tumors comprise neoplastic and stromal cell compo-
nents. Previous research has established that interactions
between cancer and stroma are important for cancer pro-
gression. Stromal cell function reportedly plays a pivotal
role during ovarian cancer tumorigenesis: infiltration of
endothelial cells into ovarian carcinoma tumors is depen-
dent on the presence of myofibroblasts [29] and stromal
infiltration, as well as vascular maturation, which
together function as a checkpoint linking angiogenesis
with the initiation of tumor progression [30]. Several stu-
dies have demonstrated that ovarian cancer cells were
able to attach to peritoneal mesothelial cells by the acti-
vation of CD44 or integrin a2b1 [31,32]. In the study by
Burleson et al., ascites spheroids (multi-cellular aggre-
gates) of ovarian carcinoma were able to adhere to live,
but non-fixed, human mesothelial cells [33,34]. Recent
analysis using surgical specimens suggested that
mesothelial cells may nurture peritoneal metastases
through the production of growth factors such as vascu-
lar endothelial growth factor (VEGF) and fibroblast
growth factor 2 (FGF2) [35], confirming Wilson’s finding
that mesothelial cells from ovarian cancer patients were
able to stimulate the clonogenic growth of ovarian tumor
cells [36]. The mutual expression of highly tumorgenic
and metastatic-related genes, such as CD44, integrin
a2b1, CD146, EGFR, and Flt-4, by epithelial- and
mesenchymal-like cells indicates that cancer-stromal
interactions of both types of cells may occur through
Figure 5 Expression of surface markers on cells deriving from OSA tissues and normal ovarian tissues. Marker expression on the surfaces
of cells (cultured in medium B) deriving from ovarian serous type adenocarcinoma tissues, analyzed using flow cytometry with various
antibodies. HOTC: mesenchymal-like cells deriving from normal ovarian tissue (n = 3). HOCTC: human ovarian cancer tissue cells (stage IIIc, n =
3). CK18 = cytokeratin 18. *Denotes a significant difference (P < 0.05) compared with HOTC samples analyzed by Student’s t-test.
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the mesenchymal stromal cells (HOTC) of normal ovar-
ian tissue, we have shown that mesenchymal like cancer
tumor fibroblasts (HOCTC) sprouting from ovarian can-
cer tissue expressed higher levels of BMP2, BMP4 and
TGF-b, which are highly associated with tumorigenesis
and metastasis. These cells also had higher expressions of
angiogenic-related markers (e.g. KDR, Flt-4, and CD31),
tumorigenic molecules (CD24
low/CD44
high, AC133), pro-
genitor characteristic markers (CD117, CD34, CD14, and
CD146) and a diminished expression of mesenchymal
cell adhesion molecules (e.g. CD24, CD49d, CD49f, SH2,
and SH4) (Figure 5). These results are consistent with
the characteristics of stromal (mesenchymal) stem cells
in human ovarian tumor microenvironment (CA-MSCs)
recently reported by McLean et al. [37], suggesting that
Figure 6 Expression of surface markers on cells deriving from ascites and OSA tissues of patients, and ascites of endometriosis
patient. Flow cytometric analysis of surface marker expression by the mesenchymal-like (n = 8) or epithelial-like cells (n = 3) (cultured in
medium B) deriving from the ascites of patients with ovarian adenocarcinoma (HOCAC; stage IIIc) and cells (cultured in medium B) (HOCTC)
deriving from cancer tissues of patients with ovarian adenocarcinoma (stage IIIc, n = 3); and cells deriving from benign ascites of patients with
endometriosis (HBAC). *Denotes a significant difference (P < 0.05) compared with HOTC samples analyzed by Student’s t-test.
Figure 7 Expression of surface markers on single-cell clones and the original mesenchymal-like cells. Flow cytometric analysis of surface
marker expression by cells (passage 6, cultured in medium B) of single-cell clone 1C3 deriving from the mesenchymal-like cell population
isolated from the ascites of a patient with OSA (#13) and the original mother cells (passage 6, cultured in medium B).
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promoting tumorigenesis via altered BMP expression, as
the CA-MSCs.
Martinet et al. recently isolated hospicells (ascites-
deriving stromal cells) from the ascites of FIGO stage III
ovarian cancer patients [38]. These could promote
tumorigenicity and angiogenesis by increasing HIF1 and
VEGF expression [22]. In the present study, the molecu-
lar markers of progenitors in cells isolated from ascites
and tumor tissues of patients with advanced or recur-
rent ovarian cancer were the highly expressed EGFR
and Flt-4 (VEGF receptor) (Figure 6), which are impor-
tant during tumor angiogenesis and metastasis. These
results agree with reported findings in hospicells [22].
To our knowledge, this is the first study to report the
isolation of cells with different morphologies, epithelial
type, and mesenchymal type, from the ascites and tumor
tissues of patients with epithelial ovarian adenocarcino-
mas, which could represent the stem/progenitor cells in
ovarian adenocarcinoma. These ovarian adenocarcinoma
stem/progenitor cells may possess the ability for EMT,
as indicated by the presence of specific molecular mar-
kers, which may function to program this process. The
established in vitro culture system provides an ideal
model for further investigation of drugs that target can-
cer-associated stromal/progenitor cells, and for the
development of effective ovarian cancer treatments. Ulti-
mately, understanding the complex molecular networks
among stromal cells and tumor cells will provide useful
information for the therapeutic targeting of human
cancers.
Conclusions
The present study established and validated an in vitro
culture system for the future screening of drugs target-
ing the ovarian cancer-associated stromal progenitor
cells, providing an alternative tool for the development
of effective ovarian cancer therapy. The obtained
ascites-originating cells with epithelial morphology and
epithelial-specific markers more frequently derived from
EOA patients at an earlier stage; mesenchymal type cells
mostly derived from EOA patients at late stage and
recurrent tumors. Both cell populations displayed the
potential for self-renewal and EMT capabilities during
the in vitro culture process.
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